Cargando…
Update on the treatment of ankylosing spondylitis
Non-steroidal anti-inflammatory agents (NSAIDs) remain the mainstay of treatment for ankylosing spondylitis (AS) though one recent trial suggests that continuous as opposed to on-demand use may be superior in preventing progression of structural damage. One particular NSAID, which is a highly select...
Autor principal: | Maksymowych, Walter P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387283/ https://www.ncbi.nlm.nih.gov/pubmed/18516314 |
Ejemplares similares
-
What do biomarkers tell us about the pathogenesis of ankylosing spondylitis?
por: Maksymowych, Walter P
Publicado: (2009) -
Updates on ankylosing spondylitis: pathogenesis and therapeutic agents
por: Kim, Se Hee, et al.
Publicado: (2023) -
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
por: Braun, J, et al.
Publicado: (2011) -
Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007) -
Ankylosing spondylitis traumatic subaxial cervical fractures – An updated treatment algorithm
por: Mehkri, Yusuf, et al.
Publicado: (2021)